Toward New Therapies For Dyskinesia
Fisone and his colleagues have previously found that, in the rat, dyskinesia is accompanied by abnormally high levels of phosphorylated DARPP-32, the “master molecule” through which dopamine signals. The researchers will use the newly developed mouse model of dyskinesia to examine how abnormal DARPP-32 phosphorylation is involved. They will also identify any changes at the level of specific signaling pathways and/or neurotransmitter systems that might be responsible for the aberrant phosphorylation of DARPP-32 associated with dyskinesia. This information will be used to select a number of candidate drugs that will be screened for efficacy in laboratory tests, thereby providing a basis for the design of novel pharmacological treatments for Parkinson’s disease. The battery of tests the researchers have designed will serve as a paradigm for future studies aimed at screening novel Parkinson’s treatments in mice.
Solutions Within Reach
These are just a few of the many lines of research our Center is pursuing in its quest to identify novel proteins and substances that can be used to develop drug therapies in the battle against Parkinson’s disease. These investigations capitalize on the team’s vast knowledge of dopamine signaling systems in the brain, and employ a multidisciplinary approach that advances the research in the most efficient ways possible. New drug targets are months, not years, away.
Clearly, this outstanding team of scientists has the right stuff to make the dream of effective new Parkinson’s treatments a reality. With the right resources supporting them, the dream will become a reality sooner rather than later.